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The condensation of 7-amino-4-methyl-coumarin (1) with a number of substituted salicylaldehydes
yielded a series of Schiff bases (2a–2k) in good yields. Subsequent reaction of these ligands with cop-
per(II) acetate yielded Cu(II) complexes (3a–3k) and some were characterised using X-ray crystallogra-
phy. All of the free ligands and their metal complexes were tested for their anti-Candida activity. A
number of the ligands and complexes exhibited anti-Candida activity comparable to that of the commer-
cially available antifungal drugs, ketoconazole and Amphotericin B.
 2009 Elsevier Inc. All rights reserved.1. Introduction
Fungal pathogens represent the major eukaryotic agents of seri-
ous infection in European countries [1]. Infections due to Candida
albicans and Aspergillus fumigatus are the most common and clini-
cally important pathogens and indeed Candida now ranks as the
fourth most common cause of nosocomial bloodstream infections
[2]. In some cases, such as patients with malignant haematological
disease and in bone-marrow transplant recipients, candidosis is
the most common invasive fungal infection [3]. The development
of azole-based antifungal drugs has considerably impacted on the
fight against fungal infections, but the necessity to use high doses
or combinations of drug therapies results in considerable side
effects in patients and resistance to these drugs has also been
reported [4–6]. Indeed, the repertoire of available antifungal
chemotherapeutic agents is inadequate to treat life-threatening
infections that are characterised by morbidities that exceed those
due to the most important bacterial and viral diseases [7–13].
Therefore, there is an urgent need to generate new, efficacious,
non-toxic compounds with broad-spectrum antifungal activity.ll rights reserved.
ience, Institute of Technology
x: +353 1 4042700.
nie.creaven@ittdublin.ie (B.S.Derivatives of coumarin are known to possess significant anti-
fungal as well as antibacterial properties, and there are a number
of commercially available coumarin-based antibiotics such as
Novobiocin, Clorobiocin and Coumermycin A1. Many of the couma-
rins present in plants, and also their synthetic analogues, have
been reported to be good antifungal and antibacterial agents
[14–21]. Preliminary structure–activity relationship studies have
shown that the presence of hydroxyl or carboxylic groups on the
coumarin nucleus are necessary for antimicrobial activity [22].
We have previously published a number of studies on both carbox-
ylate- and hydroxy-substituted coumarin ligands, and while the li-
gands themselves were not active against fungal species a number
of their Ag(I) and Cu(II) complexes showed good antimicrobial
activity [23–25]. Indeed, the silver carboxylate complexes showed
excellent activity against MRSA but they were less promising anti-
fungal agents [24]. A series of Cu(II) coumarin dioxyacetic acetate
complexes displayed promising antibacterial activity but also
showed reduced activity against fungal strains [25].
Schiff bases are a class of compound which is known to exhibit
antifungal activity [26,27]. Schiff bases derived from 5-nitrosalicyl-
aldehyde and amines, such o- and p-aminophenols, were prepared
by Murthy et al. [28] and a number of metal complexes of the
resulting ligands were tested for their antibacterial activity. Raman
et al. have recently reviewed a series of transition metal complexes
of Schiff bases derived from 4-aminoantipyrine and reported their
Table 1
Starting aldehyde and identification of functional groups on Schiff bases 2a–2k.
Starting aldehyde Schiff
base
R1 R2 R3
2-Hydroxybenzaldehyde 2a –H –H –H
2,3-Dihydroxybenzaldehyde 2b –OH –H –H
2,4-Dihydroxybenzaldehyde 2c –H –OH –H
2-Hydroxy-3-methoxybenzaldehyde 2d –OCH3 –H –H
2-Hydroxy-3-ethoxybenzaldehyde 2e –OCH2CH3 –H –H
2-Hydroxy-4-methoxybenzaldehyde 2f –H –OCH3 –H
3,5-Dichloro-2-hydroxybenzaldehyde 2g –Cl –H –Cl
3,5-Dibromo-2-hydroxybenzaldehyde 2h –Br –H –Br
3,5-Diiodo-2-hydroxybenzaldehyde 2i –I –H –I
2-Hydroxy-5-nitrobenzaldehyde 2j –H –H –NO2
2-Hydroxy-3-methoxy-5-
nitrobenzaldehyde
2k –OCH3 –H –NO2
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plexes were active against bacterial strains but not particularly
effective against C. albicans. Coumarin-derived Schiff bases are well
known compounds and several reports have been written about
their applications as dye and fluorescent agents [30,31]. Imi-
nocoumarins have also been shown to exhibit anti-inflammatory,
antibacterial and antifungal activities [32–35].
Cu(II) complexes of some organic drugs have been the subject of
a number of studies aimed at establishing the presumed synergy
between the Cu(II) ion and the drug [36–39]. In more recent years
there have been numerous reports highlighting the significant bio-
logical activity of Cu(II) Schiff base complexes [40–46]. Patil et al.
detailed the preparation of Co(II), Ni(II) and Cu(II) complexes with
1,2,4-triazole-derived coumarin Schiff bases and assessed their
biological activity [47]. In this work, we have prepared a series of
coumarin-derived Schiff bases and their Cu(II) complexes and the
anti-Candida activity of the metal-free ligands and the complexes
were assessed. Included, are the first crystal structures of Cu(II)
Schiff-base coumarin complexes.Table 2
Crystal data and structure refinement for the complexes 3a and 3h.
Complex 3a 3h
Empirical formula C68H48Cu2N4O12 C34H20Br4CuN2O6
Formula weight 1240.18 935.70
Temperature 89(2) K 89(2) K
Wavelength 0.71073 Å 0.71073 Å
Crystal system Triclinic Monoclinic
Space group P  1 P21/n
Unit cell dimensions a = 8.9076(5) Å a = 12.2159(18) Å
a = 103.436(3) a = 90
b = 12.2384(7) Å b = 9.5253(13)
b = 102.099(3) b = 92.623(8)
c = 13.5807(8) Å c = 27.093(4) Å
c = 105.233(3) c = 90
Volume 1330.35(13) Å3 3149.2(8) Å3
Z 1 4
Density (calculated) 1.548 Mg/m3 1.974 Mg/m3
Absorption coefficient 0.875 mm1 5.820 mm1
Crystal size 0.52  0.06  0.06 mm3 0.40  0.10  0.02 mm32. Experimental
2.1. Materials/instrumentation
All chemicals purchased from Sigma–Aldrich were reagent
grade and used without purification. Infrared spectra were re-
corded in the region of 4000–400 cm1, on a Nicolet Impact 410
Fourier-Transform Infrared spectrophotometer using Omnic soft-
ware. Melting point values were measured using a Stuart scientific
SMP1 melting point apparatus (up to 320 C). 1H NMR spectra were
recorded in the region of 5 to 15 ppm from TMS with a resolution
of 0.0006 ppm. 13C NMR spectra were recorded in the region 33
to 233 ppm from tetramethyl silane (TMS) with a resolution of
0.008 ppm. All of the NMR spectra were run on a JEOL JNM-
LA300 FT–NMR (300 MHz 1H and 75 MHz 13C) in d6-DMSO. Atomic
absorption spectroscopy (AAS) measurements were taken on a Per-
kin–Elmer 460 AAS instrument (emission wavelength 324.8 nm).
UV–visible (UV–vis) spectra were recorded on a Hitachi U-2001
Spectrophotometer. Microanalytical data were provided by the
Microanalytical Laboratory, National University of Ireland Dublin,
Belfield, Dublin 4. Solid state magnetic susceptibility measure-
ments were carried out at room temperature using a Johnson Mat-
they Magnetic Susceptibility Balance with Hg[Co(SCN)4] being
used as a reference standard.
2.2. Synthesis of 7-amino-4-methylcoumarin (1)
7-Amino-4-methyl-coumarin (1) was synthesised via a one
step von Pechmann reaction using a modified literature procedure
[48].17
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Fig. 1. Structure of the Schiff bases (2a–2k) showing the numbering system used in
the assignment of 1H and 13C NMR spectra.2.3. Synthesis of Schiff base ligands
All of the Schiff bases 2a–2k (Fig. 1 and Table 1) were synthes-
ised using the following general procedure. A solution of the
appropriate aldehyde (3 mmol) in ethanol (10 mL) was added
slowly to a solution of 1 (0.52 g, 3 mmol) in ethanol (50 mL) (see
Table 2). Glacial acetic acid (0.25 mL) was then added and solution
was heated under reflux for 2 h. After cooling, the product was iso-
lated by filtration, washed with cold methanol and allowed to dry
in air. The Schiff bases 2a–2g were recrystallised from ethanol
(100 mL). Assignments of NMR spectra of the ligands are based
on the numbering scheme shown in Fig. 1. Substituents R1, R2,
and R3 of the aldehyde moiety are given in Table 1. All of the li-
gands were fully characterised by 1H, 13C NMR, IR, and UV–vis
spectroscopies as well as by melting point and elemental analysis
(Tables 3–6).Index ranges 11 < = h < = 11 15 < = h < = 15
15 < = k < = 15 11 < = k < = 12
16 < = l < = 33 33 < = l < = 33
Theta range for data
collection
1.81–26.42 1.50–27.12
Reflections collected 34,790 44,071
Independent reflections 5452 [R(int) = 0.0353] 6419 [R(int) = 0.1314]
Refinement method Full-matrix least-squares
on F2
Full-matrix least-squares
on F2
Data/restraints/
parameters
5452/0/390 6419/0/426
Goodness-of-fit on F2 1.038 1.150
Final R indices
[I > 2sigma(I)]
R1 = 0.0261, wR2 = 0.0635 R1 = 0.0604, wR2 = 0.1340
R indices (all data) R1 = 0.0317, wR2 = 0.0661 R1 = 0.1058, wR2 = 0.1587
Largest diff. peak and
hole
0.322 and 0.359 e.Å3 1.620 and 1.115 e.Å3
Table 3
Physical data for the Schiff base ligands 2a–2k and their corresponding Cu(II) complexes 3a–3k.
Compound Mw (g/mol) leff (B.M.) Yield (%) Empirical formula Found (calc) (%) m.p. (C) KM (S cm2/mol)
C H N Cu
2a 279.29 – 78 C17H13NO3 73.34 (73.13) 4.77 (4.66) 5.05 (5.01) 10.3 (10.0) 178–180 –
3a 1240.18 1.63(2.28*) 80 C34H24CuN2O8 65.31 (65.85) 3.77 (3.90) 4.38 (4.52) 230–232 10.71
2b 295.3 – 89 C17H13NO4 68.87 (69.15) 4.34 (4.44) 4.78 (4.74) 9.7 (10.5) 238–240 –
3b 652.11 1.77 83 C34H24CuN2O8 62.49 (62.62) 3.70 (3.71) 4.15 (4.30) 300–304 21.4
2c 295.3 – 60 C17H13NO4 68.62 (69.17) 4.40 (4.44) 4.67 (4.74) 8.35 (8.6) 219–220 –
3c 652.09 1.81 76 C34H24CuN2O8 59.25 (59.26) 3.63 (3.93) 3.52 (3.64) >320 8.45
2d 309.18 – 92 C18H15NO4 69.48 (69.8) 4.71 (4.89) 4.43 (4.53) 9.3 (10.0) 200–202 –
3d 680.16 1.97 70 C36H28CuN2O8 63.26 (63.57) 4.14 (4.15) 3.81 (4.12) 304–306 3.68
2e 323.36 – 77 C19H17NO4 70.40 (70.58) 5.33 (5.30) 4.48 (4.33) 9.0(7.6) 150–152 –
3e 708.21 – 37 C38H32CuN2O8 62.67 (64.44) 4.95 (4.55) 3.85 (3.96) 232–238 –
2f 309.32 – 86 C18H15NO4 69.81 (69.89) 4.77 (4.89) 4.30 (4.53) 9.3 (8.9) 194–197 –
3f 680.16 1.98 86 C36H28CuN2O8 62.99 (60.19) 4.15 (4.29) 3.72 (3.51) >320 2.59
2g 348.18 – 66 C17H11NO3Cl2 58.37 (58.64) 3.17 (3.18) 3.52 (4.02) 8.4 (8.5) 260–262 –
3g 757.89 1.76 94 C34H20Cl2CuN2O6 53.76 (53.88) 2.75 (2.66) 3.73 (3.70) >320 14.9
2h 437.08 – 96 C17H11NO3Br2 46.82 (46.71) 2.55 (2.54) 3.01 (3.20) 6.8 (6.5) 270–273 –
3h 935.69 1.76 91 C34H20Br2CuN2O6 43.44 (43.64) 2.27 (2.15) 2.98 (2.99) 316–318 15.32
2i 531.08 – 97 C17H11NO3I2 38.37 (38.45) 2.04 (2.09) 2.64 (2.64) 5.67 (4.9) 274–276 –
3i 1123.69 2.18 81 C34H20I2CuN2O6 36.17 (36.34) 1.93 (1.79) 2.33 (2.49) 304–306 9.92
2j 324.29 – 81 C17H12N2O5 63.27 (62.96) 3.58 (3.73) 8.82 (8.64) 9.0 (8.6) 310–312 –
3j 710.11 1.76 95 C34H22CuN4O10 56.28 (57.51) 3.17 (3.12) 7.53 (7.89) >320 7.19
2k 354.31 – 91 C18H14N2O6 59.28 (61.02) 3.91 (3.98) 7.67 (7.91) 7.1 (7.3) 292–294 –
3k 770.16 1.73 94 C36H26CuN4O12 55.20 (56.14) 3.59 (3.40) 7.12 (7.27) 318–320 21.1
* Value for 2 Cu(II) atoms.
Table 4
Characteristic 1H NMR signals (ppm), peak multiplicity and coupling constants J (Hz) for the Schiff base ligands recorded in d6-DMSO.
Schiff base ligand H3(vinyl) H11(CH3) H13(CH@N) H15(OH) R1 R2 R3
2a 6.39, s 2.44, s 9.03, s 12.63, s 6.99, d, J = 8.43 7.47, t, J = 17.3 7.01, t, J = 16.65
2b 6.37, s 2.45, s 9.01, s 12.69, s 9.32, s (–OH) 6.99, dd, J = 9.54 6.82, t, J = 7.68
2c 6.31, s 2.27, s 8.90, s 13.13, s 6.36, s 10.42, s (–OH) 6.44, d, J = 10.42
2d 6.34, s 2.40, s 9.01, s 12.54, s 3.89, s (–OCH3) 7.16, dd, J = 7.39 6.93, t, J = 15..75
2e 6.38, s 2.45, s 9.04, s 12.81, s 4.09, q (–OCH2–)1.36, t (–CH3) 7.15, dd, J = 8.05 6.90, t, J = 15.72
2f 6.32, s 2.44, s 8.93, s 13.13, s 6.56, s 3.83, s (–OCH3) 6.60, d, J = 2.37
2g 5.90, s 1.73, s 8.39, s 8.10, s –Cl na* –Cl
2h 5.88, s 2.44, s 9.06, s 8.10, s –Br na* –Br
2i 6.42, s 2.50, s 9.61, s 9.88, s –I na* –I
2j 5.90, s 2.27, s 8.72, s 9.19, s na* na* –NO2
2k 6.41, s 2.25, s 8.34, s 9.22, s 8.87, s (–OCH3) na* –NO2
s – singlet, d – doublet, t – triplet, dd – double doublet, q – quatet.
* na – not assigned as signals overlapped.
Table 5
Characteristic 13C NMR signals (ppm) for the Schiff base ligands recorded in d6-DMSO.
Schiff base ligand C2 (lactone) C3 (vinyl) C4 C7 C9 C10 C11 (methyl) C13 (imine) C14 C15 (phenol)
2a 159.80 113.63 153.0 152.95 151.41 119.27 18.10 165.08 118.08 160.29
2b 159.82 113.63 153.88 152.96 151.94 118.09 18.12 165.62 119.38 149.36
2c 159.89 108.11 153.01 153.97 151.51 117.54 18.11 164.23 112.03 163.19
2d 154.93 108.92 149.24 143.38 na 113.41 13.24 160.27 114.75 148.06
2e 154.79 113.65 152.95 153.86 151.07 118.14 18.11 165.36 119.25 150.88
2f 159.78 113.41 152.88 154.04 151.36 117.77 18.03 164.12 113.09 163.25
2g 160.9 112.5 152.8 na 151.50 na 21.20 160.10 157.90 na
2h na 94.01 na na na na 25.78 158.45 na na
2i na 94.01 na na na na 25.78 160.10 na na
2j 160.9 112.5 152.59 152.8 na na 21.20 167.2 na na
2k 158.95 152.8 158.79 153.8 na na 17.36 162.36 156.2 na
na – not assigned.
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The Cu(II) complexes were prepared by the following general
method: 2.4 mmol of the appropriate ligand (2a–2k) was dissolved
in ethanol (40 mL) and a solution of copper(II) acetate (0.22 g,
1.2 mmol) in ethanol (10 mL) was added. The resulting mixturewas heated under reflux for up to 4 h. After cooling, the precipitated
product was collected by filtration, washed with water and dried in
air. 3a and 3hwere recrystallised by vapour diffusion of ethanol into
acetonitrile and dimethylformamide (DMF), respectively. Despite
repeated attempts to recrystallise the other Cu(II) complexes good
quality crystals of the remaining complexes were not obtained.
Table 6
Selected IR data (cm1) for the Schiff base ligands 2a–2k.
Schiff base m(CH@N) m(C@O) m(C–O) m(O–H)
2a 1619 1710 1270 3435
2b 1606 1722 1237 3289
2c 1599 1688 1239 3243
2d 1598 1728 1251 3248
2e 1599 1727 1246 3432
2f 1610 1733 1250 3437
2g 1596 1727 1269 3435
2h 1591 1727 1224 3430
2i 1580 1716 1325 3431
2j 1602 1720 1277 3432
2k 1599 1716 1268 3432
OOH2N
CHO
OH
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R3
R3
R2 OH
N
R1
OO
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O
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N
O
O
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+
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ethanol, Δ
(2a-2k)
3a-3k
Δ
Scheme 1. Synthesis of coumarin-derived Schiff base ligands (2a–2k) and their
corresponding Cu(II) complexes (3a–3k) (proposed structure of the complexes 3b–
3k).
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X-ray crystallographic studies were performed at the University
of Otago, New Zealand on a Bruker Kappa Apex II diffractometer
with a CCD area detector. All of the crystal structures were solved
using SHELXS-97. All structures were refined against F2 using all
data by full-matrix least-squares techniques with ShelX-86 and
SHELXL-97 [49,50]. Details of the data collections, solutions and
refinements for 3a and 3h are given in Table 2. CCDC numbers:
707548 and 707549 for 3a and 3h, respectively.
2.6. Anti-Candida susceptibility testing
The ligands, complexes and commercially available drugs, keto-
conazole and Amphotericin B, were tested against a clinical isolate
of the fungal strain, C. albicans (ATCC 10231). The anti-Candida
activities were determined using a broth microdilution susceptibil-
ity protocol (NCCLS) [51]. The screening protocol included the fol-
lowing steps: Isolates were grown for 24 h on Sabouraud dextrose
agar (SDA) plates at 37 C. Cell suspensions were prepared in ster-
ile phosphate buffered saline (PBS) to a density equal to a 1.0
McFarland standard yielding a concentration of 1  106 cells/mL
and then further diluted (1:100) with minimal media. Ligands,
complexes and the commercial drug were prepared as 1% solutions
or suspensions where appropriate in DMSO. All compounds were
tested at a range of concentrations of 20, 10, 5 and 1 lg/mL, and
the plates were incubated for 24 h at 37 C. Each compound was
assessed in triplicate and three independent experiments were
performed. As most of the synthesised complexes were only solu-
ble in DMSO, the effect of the solvent on the growth of C. albicans
was also studied.
3. Results and discussion
3.1. Synthesis and characterisation of the Schiff base ligands (2a–2k)
Condensation of the amino coumarin 1with a number of substi-
tuted salicylaldehydes yielded a series of Schiff bases in good yield
(Table 3). The products were obtained by refluxing ethanolic solu-
tions of starting materials in the presence of a catalytic amount of
acetic acid (Scheme 1). Physical data and empirical formulae are
presented in Table 3. All of the ligands had good solubility in a
range of organic solvents.
The 1H- and 13C NMR spectra of the ligands were recorded in d6-
DMSO and the data are reported in Tables 4 and 5. The most char-
acteristic signal in the 1H NMR spectrum of each Schiff base was
due to the imine hydrogen singlet found in the range 8.8–
9.2 ppm. The singlet for the phenolic proton of the ortho-hydroxy
group was present in the range 10–13 ppm, the downfield shift
resulting from the intramolecular hydrogen bonding to the imine
nitrogen. If the Schiff base ligands contained other hydroxyl sub-stituents, then additional singlets appear in the range 9–11 ppm.
Where possible, the 13C NMR signals of the Schiff base ligands were
assigned with the help of CHCHiFt cross peaks and DEPT
experiments.
As expected the IR spectra of the Schiff base ligands exhibited a
strong mC@N stretching vibration in the range 1619–1591 cm1 (Ta-
ble 6). The medium intensity bands in the region 1224–1277 cm1
were assigned to the phenolic mC–O stretch. A broad band at ca.
3400 cm1 was assigned to the mOH stretch. The breadth of this
band can be explained as the effect of intramolecular hydrogen
bonding between the imine nitrogen and the hydrogen from the
ortho-hydroxyl group [52,53].
The UV–vis spectra of the Schiff bases contained hypochromic
absorption bands in the ultraviolet region of the spectra corre-
sponding to the p? p* transitions of the aromatic rings and of
the conjugated system arising from the imine and coumarin moie-
ties. Low intensity, broad bands, with absorption maxima at ca.
430 nm, were assigned to forbidden n? p* transitions associated
with the azomethine group [30,52,53].
3.2. Synthesis and characterisation of the Cu(II) complexes (3a–3k)
The appropriate ligand (2a–2k) was reacted with copper(II) ace-
tate in a ratio of 2 ligand:1 Cu(II) in refluxing ethanol to give the
corresponding copper(II) complexes (3a–3k) (Scheme 1). With
Table 8
Selected UV–vis data for the Schiff base ligands and their Cu(II) complexes recorded in
DMSO.
Schiff base Complex
kmax (nm) e (M1 cm1) kmax (nm) e (M1 cm1)
(2a) (3a)
300 65,520 343 129,000
353 37,650 422 51,400
(2b) (3b)
290 63,000 339 135,600
354 36,030 421 44,900
686 1090
(2c) (3c)
280 96,930 351 59,650
354 112,300 436 67,870
672 1900
1200 B.S. Creaven et al. / Journal of Inorganic Biochemistry 103 (2009) 1196–1203the exception of 3e and 3f the microanalytical data corresponded
to an empirical formulation of 1 Cu2+ and 2 deprotonated Schiff
base ligands (Table 3). Somewhat unsatisfactory results for several
other complexes (3b, 3d, 3i, 3j and 3k) may well be due to the poor
solubility of these compounds generally which made recrystallisa-
tion of the complexes difficult. Despite repeated attempts to pre-
pare a pure Cu(II) complex of 2e, we were unable to do so and
no antimicrobial screening of 3e was carried out. Most of the
resulting complexes were soluble only in DMSO or DMF. The poor
solubility of complexes (3d, 3g, 3j and 3k) prevented the recording
of reliable UV–vis and conductivity measurements and it also
meant that the antimicrobial screening of these complexes had
to be carried out as suspensions.
3.2.1. IR spectra of Cu(II) complexes
In the IR spectra of almost all the complexes the mCN stretching
vibration associated with the imine functional group of the ligand
was shifted to a lower wavelength compared to that in the corre-
sponding free ligand, indicating that coordination to the Cu(II)
ion occurs via the imine nitrogen (Table 7) [54,55]. The mC@O
stretching vibration of the carbonyl function in the lactone ring
of the free ligands appeared as a strong sharp band in the range
1688–1733 cm1. In the spectrum of most of the complexes, the
position of this band remained largely unchanged, suggesting that
the lactone carbonyl oxygen is not involved in coordination to the
metal [56]. Upon complexation, the phenolic mC–O stretching vibra-
tion shifted to lower frequency, suggesting coordination of this
oxygen atom. Several new bands present in the region 400–
600 cm1 in the spectra of the complexes were assigned to mCu–N
and mCu–O stretching vibrations [52–55].
3.2.2. UV–vis spectra of Schiff bases and their Cu(II) complexes
UV–vis spectra of only two complexes could be reliably re-
corded over the full range due to solubility problems. Compared
to the UV–vis spectra of the free ligands, significant changes in
the wavelengths of absorption maxima were observed in those of
the corresponding complexes (Table 8). All the spectra of the com-
plexes contained broad bands in the UV region, with tailing into
the visible region. The high energy bands at ca. k = 340 nmwere as-
signed to a ligand to metal change transfer (LMCT) transition, and
the lower energy band in the region of ca. k = 420 nm were as-
signed to a metal to ligand change transfer (MLCT) transition
[52]. A low intensity absorption band in the visible region of the
spectra of concentrated solutions of 3b and 3c correspond to a
d? d* transition, but solubility problems at high concentrations
meant that the extinction coefficients at these wavelengths of
other compounds are probably not accurate.
3.2.3. Magnetic properties of Cu(II) complexes
Values of magnetic susceptibility (leff) for the Cu(II) complexes
are given in Table 3. A mononuclear Cu(II) structure is assigned toTable 7
Selected IR data (cm1) for the Cu(II) complexes 3a–3k.
Complex m(CH@N) m(C@O) m(C–O)
3a 1607 1697 1266
3b 1592 1719 1264
3c 1590 1701 1233
3d 1590 1725 1245
3e 1586 1727 1219
3f 1592 1726 1236
3g 1598 1735 1263
3h 1592 1734 1219
3i 1588 1735 1313
3j 1600 1719 1248
3k 1595 1719 1257complexes 3b–3k as the leff value for these complexes varied from
1.73 to 2.18 B.M., and is characteristic for this type of Cu(II)com-
plex [57–63]. The leff value for complex 3a was 1.63 B.M. and is
characteristic of a binuclear complex in which there is anti-ferro-
magnetic coupling between the Cu(II) centres [59,60].
3.2.4. Molar conductivity
Determination of molar conductivities was carried out on those
complexes that had good solubility in DMSO and the results ob-
tained are given in Table 3. The molar conductivity values deter-
mined for the complexes were in the range of 2.50–21.4 S cm2/
mol, and were consistent with those recorded for other Cu(II) Schiff
base complexes and would suggest their non-electrolytic character
[64,65].
3.2.5. Crystal structure analysis
The structures of the copper(II) complexes 3a and 3h were
determined by X-ray crystallography. The structure of complex
3a is shown in Fig. 2 and to our knowledge this is a first example
of a binuclear Cu(II) complex of a coumarin Schiff base. Selected
bond distances and angles are given in Table 9. The complex 3a
is centrosymmetric and the coordination about each Cu(II) centre
is completed with one imine nitrogen and one phenolic oxygen
from a single Schiff base ligand, a bridging phenolic oxygen from
an additional ligand which also provides a further imine nitrogen
to coordinate singly to the metal centre. The final coordination site
for each Cu(II) ion is filled by a phenolic oxygen atom from the sec-
ond bridging Schiff base ligand. Therefore, each Cu(II) centre is
bound to three Schiff base ligands with a different coordination
mode to each ligand. Each Cu(II) ion is primarily in a coordination
environment that may be considered as intermediate between dis-
torted trigonal bipyramidal and a square pyramidal [66,67]. The
copper ions are bridged by the two phenolic oxygen atoms with
a short copper–copper distance of 2.61 (5) ÅA
0
and a Cu–O6–Cu angle
of 103.69 (5). The rigid structure of the aromatic rings of ortho-
substituted phenolic moieties usually favours square planar or
square pyramidal coordination modes but the bulkiness of the li-
gand in this case causes a distortion of the trigonal bipyramidal
structure. The known binuclear complex of bis(N-phenyl-5-
chloro-salicylideneaminato)copper(II), has a coordination geome-
try around the Cu(II) ion which is similar to that of 3a [68].
The crystal structure of 3h (Fig. 3) shows a mononuclear Cu(II)
centre bound to two Schiff base ligands. The bond lengths and an-
gles (Table 9) suggest a distorted square planar coordination envi-
ronment for the metal [67]. Coordination of the Cu(II) centre to
both ligands is via the imine nitrogen and phenolic oxygen atoms.
Bond lengths between the Cu(II) centre and the donor atoms are
consistent with previously reported compounds of similar struc-
tures [54,67]. There is no centre of symmetry in the molecule
Fig. 2. Crystal structure of 3a.
Table 9
Selected bond lengths (Å) and angles () for 3a and 3h.
Cu(1)–O(3) 1.8820 (11) Cu(1)–O(6) 1.895 (4)
Cu(1)–O(6) 1.9152 (11) Cu(1)–O(3) 1.897 (5)
Cu(1)–N(1) 2.0379 (14) Cu(1)–N(2) 1.973 (5)
Cu(1)–N(2) 2.0674 (14) Cu(1)–N(1) 2.001 (5)
Cu(1)–O(6)#1 2.2785 (12) N(1)–C(11) 1.291 (9)
N(1)–C(8) 1.441 (8)
O(3)–C(13) 1.308 (8)
O(3)–Cu(1)–O(6) 169.13 (5) O(6)–Cu(1)–O(3) 154.7 (2)
O(3)–Cu(1)–N(1) 91.02 (5) O(6)–Cu(1)–N(2) 93.5 (2)
O(6)–Cu(1)–N(1) 93.98 (5) O(3)–Cu(1)–N(2) 89.1 (2)
O(3)–Cu(1)–N(2) 94.04 (5) O(6)–Cu(1)–N(1) 93.0 (2)
O(6)–Cu(1)–N(2) 89.52 (5) O(3)–Cu(1)–N(1) 92.6 (2)
N(1)–Cu(1)–N(2) 133.42 (5) N(2)–Cu(1)–N(1) 161.0 (2)
O(3)–Cu(1)–O(6)#1 92.91 (5) C(11)–N(1)–Cu(1) 123.2 (4)
O(6)–Cu(1)–O(6)#1 76.37 (5) C(8)–N(1)–Cu(1) 121.6 (4)
N(1)–Cu(1)–O(6)#1 108.19 (5) C(13)–O(3)–Cu(1) 128.6 (4)
N(2)–Cu(1)–O(6)#1 117.72 (5) C(31)–N(2)–Cu(1) 124.2 (5)
C(28)–N(2)–Cu(1) 120.8 (4)
C(33)–O(6)–Cu(1) 128.9 (4)
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tween copper and each of the nitrogen atoms of the two ligands
coordinated to it; 1.973(5) Å for Cu(1)–N(2) and 2.001(5) Å for
Cu(1)–N(1). The low symmetry in the molecule is also reflected
in the relative OCuN bond angles; O(6)–Cu(1)–N(2) is 93.5(2)
and O(3)–Cu(1)-N(1) is 92.6(2). The crystal packing diagram
(Fig. 4) indicates aryl–aryl stacking interactions between the ring
systems of adjacent molecules.
3.2.6. Anti-Candida activities of Schiff Base ligands and Cu(II)
complexes
It has previously been reported that the amount of DMSO which
is used to prepare samples for assessment of anti-Candida activity
can affect the growth of the test strain used [69]. Therefore, before
we tested the anti-Candida activity of the free ligands and their cor-
responding Cu(II) complexes we assessed the influence of the
DMSO solvent on the growth of the Candida strain. The results indi-
cated that the presence of 10% DMSO in the test mixture was
highly toxic to the Candida cells, causing nearly 100% growth
inhibition. 5% DMSO affected nearly 80% growth inhibition of theCandida cells, and was also not suitable for the further studies.
Reducing DMSO concentration to 2% resulted in approximately
55% growth inhibition. Finally it was found that the presence of
1% of DMSO in the test mixture did not affect the growth of the
fungus. Therefore, it was decided that for the available strain of
C. albicans, the maximal final concentration of DMSO that can be
used in the assay cannot be higher than 1%.
The anti-Candida activity of the Schiff base ligands (2a–2k) and
their Cu(II) complexes (3a–3k, except 3e) expressed as MIC50 val-
ues (the minimum concentration required to inhibit 50% of cells
growth) is specified in Table 10. A number of the free ligands
and complexes displayed anti-Candida activity comparable to
those of the commercially available antifungal drugs, Amphoteri-
cin B and ketoconazole.
In our previous work on coumarin compounds, involving deri-
vatised coumarin-3-carboxylic acids, 4-hydroxy-3-nitrocoumarin
and coumarin dioxyacetic acid ligands, it was shown that none of
the ligands had significant anti-Candida activity [23–25]. The re-
sults presented here show that a while a number of the coumarin
Schiff base ligands have reasonable high MIC50 values, those of the
halogenated and nitro derivatives are very low and are comparable
to that of the commercially used antifungal agents, Amphotericin B
and are indeed lower than that of the commercial drug, ketocona-
zole. In particular, the diiodo-substituted compound, 2i
(MIC50 = 1.2 lM), was particularly active. These results also agree
with the findings of Guo et al. who demonstrated that Schiff bases
containing 2-hydroxy-5-nitro and 5-chloro-2-hydroxy-substituted
aromatic rings have good antifungal activities [71]. Because of sol-
ubility problems a few of the Cu(II) complexes were tested as
DMSO suspensions. Cu(II) acetate did not show anti-Candida activ-
ity at any of the test concentrations. Overall, complexes with good
solubility in DMSO showed higher activity than those with poor
solubility, but almost all complexes showed considerably in-
creased activity over their corresponding metal-free Schiff base li-
gand. Interestingly, the complexes with dichloro and dibromo
substituents on the ligand (3g and 3h) exhibited high anti-Candida
activity even as a DMSO suspension in the case of 3g. Complex 3i
was the most active of the series and maintained its significant
activity (65% growth inhibition) even at a concentration of 1 lg/
mL.
Fig. 3. Crystal structure of 3h.
Fig. 4. Packing diagram for 3h.
Table 10
Anti-Candida activity of Schiff base ligands and their Cu(II) complexes. See Fig. 1 for ligand structures and carbon and substituent numbering.
Ligand MIC50 (lM) Cu(II) complex MIC50 (lM) R1 R2 R3
2a 92.3 3a 5.2 –H –H –H
2b 35.4 3b 10.4 –OH –H –H
2c 89.2 3c 16.7 –H –OH –H
2d 62.0 3d 8.2 –OCH3 –H –H
2e 92.6 3e – –OCH2CH3 –H –H
2f 44.5 3f 14.5 –H –OCH3 –H
2g 17.1 3g 3.6 –Cl –H –Cl
2h 3.2 3h 4.4 –Br –H –Br
2i 1.2 3i 0.7 –I –H –I
2j 9.1 3j 9.8 –H –H –NO2
2k 95.4 3k 12.6 –OCH3 –H –NO2
Amphotericin B 0.7
Ketoconazole* 4.7
* Value recorded previously in our lab under the same conditions [70].
1202 B.S. Creaven et al. / Journal of Inorganic Biochemistry 103 (2009) 1196–1203In general, it was found that Schiff base ligands with electron-
withdrawing substituents such as –Cl, –Br, or –I, at the R1 and R3
positions of the salicylaldehyde moiety had greater anti-Candidaactivity than ligands with electron-donating substituents. Surpris-
ingly, the complexation of these active ligands to Cu(II) ions re-
sulted in only slight increases in the activity of the subsequent
B.S. Creaven et al. / Journal of Inorganic Biochemistry 103 (2009) 1196–1203 1203complexes. This is in stark contrast to the behaviour of the less ac-
tive ligands (2a–2f, 2k), whose Cu(II) complexes (3a–3d, 3f, 3k) in
all cases were significantly more active against Candida. It is diffi-
cult to attribute these trends to changes in solubility alone. All of
the ligands were freely soluble in a range of organic solvents
whereas only some of the metal complexes were soluble in DMSO
or DMF. Some of the most active complexes, i.e. 3d, 3g and 3j were
tested as suspensions and their MIC50 values were still lower than
those of their corresponding free ligands. Previous work by Nair
et al. reported a series of Mn(II) and Cu(II) complexes which exhib-
ited activities lower than the activities of their corresponding free
ligands when tested using separately 1,4-dioxane and DMF as sol-
vent [72].
This present study has identified a series of coumarin-derived
Schiff bases and their Cu(II) complexes who have displayed good
antifungal activity against a clinical strain of C. albicans. We have
also reported the first crystal structures of this type of metal
complex.
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